This mind-blowing study revealed how berberine lowers LDL cholesterol through a mechanism that’s completely different from ...

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is highly expressed in adult hepatocytes. PCSK9 binds to and promotes the degradation of the low-density lipoprotein (LDL) receptor, thereby ...

The U.S. government's premier research body has made an important discovery that could help create new drugs to lower "bad" cholesterol, and hopefully prevent heart attacks and stroke. But the ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep further reduced LDL vs. placebo in well-treated patients with HeFH. More than 85% of the ...

Pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) are produced in large quantities locally in the joints and subsequently enter the bloodstream. TNF-α and IL-6 may promote LDL metabolism by ...

Patients with severe hypercholesterolemia who are unresponsive to a number of lipid-lowering therapies, including a PCSK9 inhibitor and high-dose statin, can have a significant reduction in ...

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...

High levels of low-density lipoprotein (LDL) cholesterol can cause artery blockages and diseases like heart attacks and strokes. Further, it raises the risk of cardiovascular disease (CVD). Thickened ...